SCHEMBL4100975

SCHEMBL4100975

CSc1nc(-c2cc(OCc3ccccc3)c(Cl)cc2Cl)c2nc[nH]c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 3/20 0.43
KCNH2 Q12809 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.38
RHEB Q15382 1/20 0.37
PPARG P37231 1/20 0.37
GRM4 Q14833 1/20 0.37
IDO1 P14902 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
STAT3 P40763 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 1/20 0.35
CNR1 P21554 4/20 0.35
MRGPRX4 Q96LA9 1/20 0.34
GCK P35557 1/20 0.34
PPIA P62937 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084482 0.86 L3MBTL1 (0.41) L3MBTL1RHEBGRM4IDO1KDM4E
SCHEMBL12160975 0.82 HSP90AB1 (0.51) HSP90AB1KCNH2L3MBTL1RHEB
SCHEMBL13798713 0.79 HSP90AB1 (0.69) HSP90AB1KCNH2
SCHEMBL4094400 0.75 HSP90AB1 (0.55) HSP90AB1KDM4ECYP1A2CYP2C19
SCHEMBL4101361 0.74 CCR5 (0.37) HSP90AB1KCNH2RHEBCYP2C19SMN1; SMN2
SCHEMBL4089936 0.73 HSP90AB1 (0.60) HSP90AB1KCNH2KDM4ECYP2C19
SCHEMBL13765768 0.70 HSP90AB1 (0.68) HSP90AB1KDM4E
SCHEMBL12161021 0.70 HSP90AB1 (0.57) HSP90AB1KCNH2
SCHEMBL20535988 0.67 MAPT (0.46) L3MBTL1RHEBGRM4IDO1STAT3
SCHEMBL4098709 0.67 HSP90AB1 (0.44) HSP90AB1KCNH2KDM4EALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
EP-2004648-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER Vernalis (R&D) Limited (GB) 2008-12-24 EP disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P HSP90AB1 2/4885KCNH2 3508/4885L3MBTL1 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.